Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy.
Can J Gastroenterol Hepatol
; 2022: 4291758, 2022.
Article
in English
| MEDLINE | ID: covidwho-2194224
ABSTRACT
Following the SARS-CoV-2 outbreak and the subsequent development of the COVID-19 pandemic, organs such as the lungs, kidneys, liver, heart, and brain have been identified as priority organs. Liver diseases are considered a risk factor for high mortality from the COVID-19 pandemic. Besides, liver damage has been demonstrated in a substantial proportion of patients with COVID-19, especially those with severe clinical symptoms. Furthermore, antiviral medications, immunosuppressive drugs after liver transplantation, pre-existing hepatic diseases, and chronic liver diseases such as cirrhosis have also been implicated in SARS-CoV-2-induced liver injury. As a result, some precautions have been taken to prevent, monitor the virus, and avoid immunocompromised and susceptible individuals, such as liver and kidney transplant recipients, from being infected with SARS-CoV-2, thereby avoiding an increase in mortality. The purpose of this review was to examine the impairment caused by SARS-CoV-2 infection and the impact of drugs used during the pandemic on the mortality range and therefore the possibility of preventive measures in patients with liver disease.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Liver Diseases
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Can J Gastroenterol Hepatol
Year:
2022
Document Type:
Article
Affiliation country:
2022
Similar
MEDLINE
...
LILACS
LIS